Zacks.com on MSN21h
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalShares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback